1.	A Study to Provide Access to Trabectedin in Patients With Non L-type Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR003583, ET743SAR3002, NCT00210665
2.	Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: E7389-G000-309, NCT01327885
3.	A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma Phase: Phase III Type: Treatment Status: Active Age: 15 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR018004, ET743SAR3007, NCT01343277
4.	Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: AVF4761s, 200911736, NCT01106872
5.	Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2011-01412, 10-049, CDR0000680558, MSKCC-10049, U01CA069856, 8406, NCT01154452
6.	A Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BBI608-201, NCT01325441
7.	Aerosol IL-2 for Pulmonary Metastases Phase: Phase II, Phase I Type: Treatment Status: Active Age: 12 and over Sponsor: Other Protocol IDs: 2010-0700, NCT01590069
8.	Proton RT for Retroperitoneal Sarcomas Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 12-100, NCT01659203
9.	Radiation Therapy to Treat Musculoskeletal Tumors Phase: Phase II Type: Treatment Status: Active Age: 25 and under Sponsor: Other Protocol IDs: RTSARC, NCT00186992
10.	Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: 05-122, MSKCC-05122, NCT00445965
11.	Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas Phase: Phase II Type: Treatment Status: Active Age: 30 and under Sponsor: NCI, Other Protocol IDs: 05-326, Other, NCT00592293
12.	Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 08-1299 / 201109179, NCT00802880
13.	Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 090192, 09-C-0192, NCT00942877
14.	PD0332991 in Patients With Advanced or Metastatic Liposarcoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 10-094, NCT01209598
15.	Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma Phase: Phase II Type: Treatment Status: Active Age: Under 30 Sponsor: NCI Protocol IDs: NCI-2011-02607, ARST0921, CDR0000687113, U10CA098543, COG-ARST0921, NCT01222715
16.	Pilot Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor Phase: Phase II Type: Treatment Status: Active Age: 3 to 55 Sponsor: Other Protocol IDs: 2009-0528, NCT01277744
17.	Radiation Therapy and Intratumoral Autologous Dendritic Cells in Soft Tissue Sarcomas (STS) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MCC-16441, NCT01347034
18.	Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: ACORN ABLSMLS1101, NCT01506596
19.	Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 15 and over Sponsor: Other Protocol IDs: SOL-11130-L, NCI-2012-00052, IRB# 7943, NCT01532687
20.	A Treatment Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma Phase: Phase II Type: Treatment Status: Active Age: 18 to 90 Sponsor: Other Protocol IDs: MUSC 101644, PAZ115785, NCT01593748
21.	Trebananib in Treating Patients With Advanced Angiosarcoma That Cannot Be Removed by Surgery Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-01978, A091103, CDR0000735380, CALGB-A091103, U10CA031946, NCT01623869
22.	Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-01991, A091102, CDR0000737403, CALGB-A091102, U10CA031946, NCT01653028
23.	Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: SARC016, NCT01661283
24.	Cabozantinib for Adults With Advanced Soft Tissue Sarcoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 130044, 13-C-0044, NCT01755195
25.	A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NU 12S02, NCI-2012-03188, STU00073826, NCT01782313